Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?


Journal article


H. Moore, Christopher D. Barrett, E. Moore, R. McIntyre, Peter K. Moore, D. Talmor, F. Moore, M. Yaffe
Journal of Trauma and Acute Care Surgery, 2020

Semantic Scholar DOI PubMedCentral PubMed
Cite

Cite

APA   Click to copy
Moore, H., Barrett, C. D., Moore, E., McIntyre, R., Moore, P. K., Talmor, D., … Yaffe, M. (2020). Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome? Journal of Trauma and Acute Care Surgery.


Chicago/Turabian   Click to copy
Moore, H., Christopher D. Barrett, E. Moore, R. McIntyre, Peter K. Moore, D. Talmor, F. Moore, and M. Yaffe. “Is There a Role for Tissue Plasminogen Activator as a Novel Treatment for Refractory COVID-19 Associated Acute Respiratory Distress Syndrome?” Journal of Trauma and Acute Care Surgery (2020).


MLA   Click to copy
Moore, H., et al. “Is There a Role for Tissue Plasminogen Activator as a Novel Treatment for Refractory COVID-19 Associated Acute Respiratory Distress Syndrome?” Journal of Trauma and Acute Care Surgery, 2020.


BibTeX   Click to copy

@article{h2020a,
  title = {Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?},
  year = {2020},
  journal = {Journal of Trauma and Acute Care Surgery},
  author = {Moore, H. and Barrett, Christopher D. and Moore, E. and McIntyre, R. and Moore, Peter K. and Talmor, D. and Moore, F. and Yaffe, M.}
}

Abstract

This supported by NIH Grants UM1-HL120877 (EEM, MBY), (CDB), and L30-GM120751 (CDB); and DoD Peer Reviewed Medical Research Program, Contract Number W81XWH-16-1-0464 (MBY).